GlassScriptPhysician profile
Kristina M Moule
NPI 1891969309
$1,890.16
in general payments reported to CMS, 2019-2025
16 companies · $557 in 2025
The $557 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $118 · 2023: $518 · 2024: $561 · 2025: $557.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $522.10 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.38 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $195.82 | 2022-2024 | Camzyos, Eliquis |
| Pfizer INC. | $193.70 | 2023-2025 | |
| Edwards Lifesciences Corporation | $156.04 | 2021-2023 | Sapien 3 Ultra Resilia |
| Astrazeneca Pharmaceuticals LP | $147.55 | 2023-2025 | Farxiga, Wainua |
| Kiniksa Pharmaceuticals, LTD. | $126.26 | 2022-2023 | Arcalyst |
| Amgen INC. | $80.52 | 2023-2025 | Repatha |
| Cvrx, INC. | $48.40 | 2023 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $46.51 | 2023-2024 | Inpefa |
| Novo Nordisk INC | $45.81 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $34.34 | 2022-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $18.89 | 2024 | Xarelto |
| Inspire Medical Systems, INC. | $18.88 | 2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $16.92 | 2024 | Arcalyst |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.04 | 2023 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Moule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.